20190605 Transgene publi TG4001 TG6002 EN
Category: TG4001
The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
Diane M. Harper, et al. Gynecologic Oncology, April 2019 – Download the article The publication has been featured in The Lancet Oncology and Medpage Today Publication
Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients
20181220-Phase-1-TG4001-EN
First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
170919-Transgene-FPI-Announcement_US
Transgene Announces Collaboration with Merck and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head & Neck Cancer in a Phase 1/2 Study
alliance_transgene-collab-press-release_row
Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein.
Christelle Remy-Ziller, et al. Clinical and vaccine immunology. 2014; 21(2): 147-155 – Download the article Publication
